Deliver the best cell lines

Set your IND up for success by getting FDA-accepted monoclonality assurance in just days.

  • We’ve been able to screen more molecules per project and clones per lead, meaning we can engage with our discovery colleagues earlier.
    Robyn Emmins, Group Leader, GSK

Clone Selection in Just Days


Cell Line Development Workflow


Replace 8-12 weeks of challenging well plate steps with Opto CLD on the Beacon optofluidic system. Screen thousands of clones in parallel with advanced in-process imaging and automation and increase capacity to up to 50 campaigns.

Complex Antibody Molecules

Select top clones for even non-traditional antibody molecules, like bispecifics.​



The Opto CLD Workflow selects top clones by measuring growth and titers over multiple days of on-chip culture. SpotLight™ assays enable quantification of both traditional and non-traditional antibodies, such as Fc-engineered mAbs, bispecifics, and multispecifics.

Selection Based on Product Quality, Not Just Productivity​​

Get to production faster with Opto™ Assure for early manufacturability assessment.​​



CLD Aggregation Assay

Opto™ Assure minimizes risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality. Opto Assure assay for aggregation enables direct detection of product aggregates within days of single cell cloning. This lets you confidently identify and select clones that secrete high-quality complex molecules and develop better production cell lines faster. ​​

>99% monoclonality assurance

Get >99% monoclonality assurance with a single, automated round of cloning.

The Berkeley Lights Opto CLD workflow enables in-line controls to measure clonality during clone recovery. After recovery of each clone, media is flushed into “blank” wells to detect any residual cells. Expand >90% of selected clones from the Beacon system when recovered into 96-well plates, with >99% monoclonality assurance –  which is equivalent to four rounds of limiting dilution!

See independent validation by Le, K et al. Amgen.


FDA-accepted clonality assurance for a successful IND​

The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of >99% monoclonality, without manual effort and uncertainty of traditional methods. Learn how the Opto CLD workflow provides superior cloning technology and in-process quality controls for definitive evidence of monoclonality to support regulatory approvals.

See Application Note

Export the best from 1000s of clones

The Opto CLD Workflow enables selection of top clones by measuring growth over multiple days of on-chip culture and secretion titers using quantitative assays for both traditional and non-traditional antibodies.

  • Measure antibody production from 1000s of clones
  • Quantify secretion titers and specific (per-cell) productivity using the Spotlight™ Human Fc and SpotLight™ Human Kappa reagents
  • Enrich and recover top-secreting clones for scale-up

Spotlight assay: Simultaneous, quantitative antibody titer measurements on thousands of clones (LEFT). Clones selected based on titer measurements on the Beacon system had 1.5–3-fold higher titers than clones selected using traditional clone picking technology when scaled up to shake flask fed-batch cultures (RIGHT). ©2019 Catalent, Inc. All rights reserved.

Get in Touch with Berkeley Lights

Let us know what you are looking for and one of our experts will contact you promptly to follow up on your request.